Company Listing
Micromet

Micromet developed highly potent bi-specific antibody-based drugs for the treatment of cancer, autoimmune and inflammatory diseases. Micromet completed a reverse takeover of CancerVax in May 2006 and was acquired by Amgen for $1.2 billion in March 2012.

BACK
Location
Munich, Germany

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Company Listing

Micromet developed highly potent bi-specific antibody-based drugs for the treatment of cancer, autoimmune and inflammatory diseases. Micromet completed a reverse takeover of CancerVax in May 2006 and was acquired by Amgen for $1.2 billion in March 2012.

Location
Munich, Germany
BACK
 
Copyright Abingworth 2017